A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
Clinical Cancer Research (2011) - Comments
pubmed: 21278242  doi: 10.1158/1078-0432.CCR-10-1927  issn: 1078-0432  issn: 1557-3265 

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. De Bono, Florence Raynaud, Paul Workman, Ian Judson